share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Lagarde Michel

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Lagarde Michel

福泰製藥 | 4：持股變動聲明-董事 Lagarde Michel
美股sec公告 ·  05/04 04:23
牛牛AI助理已提取核心訊息
Vertex Pharmaceuticals Inc. (VRTX) has reported a transaction involving Michel Lagarde, a key figure at the company. The transaction, which took place on May 1, 2024, did not specify the relationship of Lagarde to the issuer. Details regarding the number of shares involved, the nature of the shares, the transaction price, and the total value of the shares after the action were not disclosed in the announcement.
Vertex Pharmaceuticals Inc. (VRTX) has reported a transaction involving Michel Lagarde, a key figure at the company. The transaction, which took place on May 1, 2024, did not specify the relationship of Lagarde to the issuer. Details regarding the number of shares involved, the nature of the shares, the transaction price, and the total value of the shares after the action were not disclosed in the announcement.
Vertex Pharmicals Inc.（VRTX）報告了一筆涉及該公司關鍵人物米歇爾·拉加德的交易。該交易於2024年5月1日進行，沒有具體說明拉加德與發行人的關係。公告中沒有披露有關所涉股票數量、股票性質、交易價格和行動後股票總價值的詳細信息。
Vertex Pharmicals Inc.（VRTX）報告了一筆涉及該公司關鍵人物米歇爾·拉加德的交易。該交易於2024年5月1日進行，沒有具體說明拉加德與發行人的關係。公告中沒有披露有關所涉股票數量、股票性質、交易價格和行動後股票總價值的詳細信息。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。